Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IGG001
MIFTS: 55

Iga Glomerulonephritis

Categories: Rare diseases, Nephrological diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Iga Glomerulonephritis

About this section

MalaCards integrated aliases for Iga Glomerulonephritis:

Name: Iga Glomerulonephritis 12 15 73
Iga Nephropathy 12 76 53 37 13
Glomerulonephritis, Iga 53 44
Primary Immunoglobulin a Nephropathy 73
Iga Nephropathy, Susceptibility to 6
Berger's Iga or Igg Nephropathy 12
Segmental Glomerulonephritis 12
Focal Glomerulonephritis 12
Glomerulonephritis Focal 55
Primary Iga Nephropathy 12
Nephritis, Iga Type 53
Berger's Disease 53
Nephropathy Iga 55
Berger Disease 53
Igan 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2986
MeSH 44 D005922
SNOMED-CT 68 236407003 68779003
KEGG 37 H01581
Sources

Summaries for Iga Glomerulonephritis

About this section
NIH Rare Diseases : 53 IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. IgA nephropathy can occur at any age, even in childhood. After many years, deposits of IgA may cause the kidneys to leak blood and sometimes protein in the urine. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. After 10 to 20 years, the kidneys may show signs of damage and 20-40% of adults develop end-stage kidney disease. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection. Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to a genetic material on the long arm of chromosome 6 (6q22-23). There is no cure for this condition. Treatment focuses on slowing the disease and preventing complications.

MalaCards based summary : Iga Glomerulonephritis, also known as iga nephropathy, is related to membranoproliferative glomerulonephritis and vasculitis. An important gene associated with Iga Glomerulonephritis is IGAN1 (IgA Nephropathy), and among its related pathways/superpathways are Complement Pathway and AGE-RAGE signaling pathway in diabetic complications. The drugs Enalapril and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and tonsil, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology : 12 A glomerulonephritis characterized by build up of IgA antibody in the glomerulus.

Wikipedia : 76 IgA nephropathy (IgAN), also known as IgA nephritis, Berger disease (/bɛərˈʒeɪ/) (and variations), or... more...

Sources

Related Diseases for Iga Glomerulonephritis

About this section

Diseases related to Iga Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 membranoproliferative glomerulonephritis 30.1 ALB CD79A CFP NPHS1
2 vasculitis 30.1 CCL2 CD40LG CD79A
3 glomerulonephritis 29.4 ALB CCL2 CD40LG CD79A CFP NPHS1
4 nephrosclerosis 29.2 ACE AGTR1 CCL2 NPHS2 TGFB1
5 microvascular complications of diabetes 3 28.6 ACE AGTR1 ALB NAGLU NPHS1 REN
6 membranous nephropathy 28.5 ACE ALB CD79A NPHS1 NPHS2 SERPINB7
7 charcot-marie-tooth disease, dominant intermediate e 11.8
8 selective igg deficiency disease 11.2 CD40LG CD79A
9 c1q nephropathy 11.2 CD40LG CD79A
10 meningovascular neurosyphilis 11.1 CD40LG CD79A
11 alpha chain disease 11.1 CD40LG CD79A
12 brill-zinsser disease 11.1 CD40LG CD79A
13 exudative glomerulonephritis 11.1 CD40LG CD79A
14 salpingo-oophoritis 11.1 CD40LG CD79A
15 early yaws 11.1 CD40LG CD79A
16 ventilation pneumonitis 11.1 CD40LG CD79A
17 chronic interstitial cystitis 11.1 CD40LG CD79A
18 axillary adenitis 11.1 CD40LG CD79A
19 iga nephropathy 1 11.1
20 cryofibrinogenemia 11.1 CD40LG CD79A
21 trichostrongyloidiasis 11.1 CD40LG CD79A
22 subacute bacterial endocarditis 11.1 CD40LG CD79A
23 heterophyiasis 11.1 CD40LG CD79A
24 orbital granuloma 11.1 CD40LG CD79A
25 transient hypogammaglobulinemia of infancy 11.1 CD40LG CD79A
26 focal embolic glomerulonephritis 11.0
27 hyperglobulinemic purpura 11.0 CD40LG CD79A
28 gastroduodenitis 11.0 CD40LG CD79A
29 bacterial conjunctivitis 11.0 CD40LG CD79A
30 loeffler syndrome 11.0 ACE CD40LG
31 immunoglobulin g deficiency 11.0 CD40LG CD79A MBL2
32 immunoglobulin alpha deficiency 11.0 CD40LG CD79A MBL2
33 focal segmental glomerulosclerosis 5 11.0
34 heavy chain disease 11.0 CD40LG CD79A
35 hyporeninemic hypoaldosteronism 11.0 ACE REN
36 ophthalmia neonatorum 11.0 CD40LG CD79A
37 pyelitis 10.9 CD40LG CD79A REN
38 immunoglobulin a deficiency 1 10.9 CD40LG CD79A
39 parotid disease 10.9 CD40LG CD79A
40 colorado tick fever 10.9 ALB CD40LG
41 renal artery obstruction 10.9 ACE REN
42 cerebral arteritis 10.9 CD40LG CD79A
43 ostertagiasis 10.9 ALB CD79A
44 streptococcal meningitis 10.9 CD40LG CFP MBL2
45 dermatitis, atopic, 3 10.9 ALB CD79A
46 hypersensitivity vasculitis 10.9 C1GALT1 CD40LG CD79A
47 selective immunoglobulin deficiency disease 10.9 CD40LG CD79A
48 3mc syndrome 10.9 CFP MASP1 MBL2
49 plasmodium malariae malaria 10.8 ALB CD40LG
50 vesicoureteral reflux 1 10.8 AGTR1 NAGLU REN

Graphical network of the top 20 diseases related to Iga Glomerulonephritis:



Diseases related to Iga Glomerulonephritis
Sources

Symptoms & Phenotypes for Iga Glomerulonephritis

About this section

MGI Mouse Phenotypes related to Iga Glomerulonephritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ALB TGFB1 C1GALT1 CD40LG CD79A CFP
2 immune system MP:0005387 9.73 TGFB1 C1GALT1 CCL2 CD40LG CD79A CFP
3 renal/urinary system MP:0005367 9.44 C1GALT1 CD40LG CD79A MBL2 NAGLU NPHS1
Sources

Drugs & Therapeutics for Iga Glomerulonephritis

About this section

Drugs for Iga Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enalapril Approved, Vet_approved Phase 4,Phase 2,Not Applicable 75847-73-3 5362032 40466924
2
Enalaprilat Approved Phase 4,Phase 2,Not Applicable 76420-72-9 6917719
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
rituximab Approved Phase 4,Phase 2 174722-31-7 10201696
6
Angiotensin II Approved, Investigational Phase 4,Phase 3,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
7
Losartan Approved Phase 4,Phase 3,Not Applicable 114798-26-4 3961
8
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
11
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
12
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
13
Probucol Approved, Investigational Phase 4 23288-49-5 4912
14
Hydroxychloroquine Approved Phase 4,Phase 2 118-42-3 3652
15
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
16
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
17
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
20
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable 32222-06-3 134070 5280453
21
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
22 tannic acid Approved, Nutraceutical Phase 4
23
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
24
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
25 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
26 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
27 Antihypertensive Agents Phase 4,Phase 3,Not Applicable
28 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
30 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
32 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
33 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
36 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
38 Immunoglobulin A Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
40 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3,Not Applicable
41 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
43 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
44 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3,Not Applicable
45 Prednisolone phosphate Phase 4,Phase 2,Phase 3,Not Applicable
46
protease inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
47 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
48 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Not Applicable
49 Angiotensin Receptor Antagonists Phase 4,Phase 3,Not Applicable
50 Angiotensinogen Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
2 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
3 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
4 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
5 Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
6 Mycophenolate Mofetil for IgA Nephropathy Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
7 Pilot Study of Velcade® in IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
8 A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
9 Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
10 "Steroids and Azathioprine Versus Steroids Alone in IgAN" Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
11 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
12 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
13 Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade Completed NCT00922311 Phase 4 Aliskiren
14 Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
15 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
16 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
17 Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Recruiting NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
18 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
19 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
20 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
21 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
22 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
23 Acthar on Proteinuria in IgA Nephropathy Patients Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
24 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
25 Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
26 BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
27 Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
28 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
29 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
30 Aliskiren for Immunoglobulin A (IgA) Nephropathy Completed NCT00870493 Phase 3 Aliskiren;Placebo
31 Steroids and Azathioprine in Advanced IgAN Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
32 Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor Completed NCT00437463 Phase 3 Ramipril
33 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
34 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie Herbal Compound;Immunosuppressive Agents
35 Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Active, not recruiting NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
36 Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Active, not recruiting NCT02282930 Phase 3 ACTH (Acthar) Gel
37 Efficacy and Safety of Losartan in Children With Ig A Nephropathy Active, not recruiting NCT02232776 Phase 3 Losartan
38 Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
39 Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
40 Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
41 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy Withdrawn NCT00599963 Phase 3 paricalcitol
42 BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
43 A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
44 The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease Completed NCT01738035 Phase 2 NEFECON
45 Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade Completed NCT02384317 Phase 2 CCX168
46 Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy Completed NCT00396721 Phase 2 ACE inhibitor + statin;Sirolimus (study drug)+ACE inhibitor + statin
47 Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study Completed NCT00767221 Phase 2 Budesonide
48 Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy Completed NCT00004448 Phase 2 omega-3 fatty acids;prednisone
49 A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients Completed NCT01224028 Phase 2 Tacrolimus;Placebo
50 A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy Completed NCT02942381 Phase 2 Hydroxychloroquine Sulfate;Placebo

Search NIH Clinical Center for Iga Glomerulonephritis

Cochrane evidence based reviews: glomerulonephritis, iga

Sources

Genetic Tests for Iga Glomerulonephritis

About this section
Sources

Anatomical Context for Iga Glomerulonephritis

About this section

MalaCards organs/tissues related to Iga Glomerulonephritis:

41
Kidney, Liver, Tonsil, T Cells, Endothelial, Monocytes, Testes
Sources

Publications for Iga Glomerulonephritis

About this section

Articles related to Iga Glomerulonephritis:

(show top 50) (show all 1131)
# Title Authors Year
1
Tonsillitis exacerbates renal injury in IgA nephropathy through promoting Th22 cells chemotaxis. ( 29549623 )
2018
2
Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. ( 29137483 )
2018
3
Night-time activation of the intrarenal renin-angiotensin system due to nocturnal hypertension is associated with renal arteriosclerosis in normotensive IgA nephropathy patients. ( 29507351 )
2018
4
Genitourinary melioidosis in a Bangladeshi farmer with IgA nephropathy complicated by steroid-induced diabetes mellitus. ( 29970750 )
2018
5
Acquired cutis laxa associated with inflammatory bowel disease, inflammatory arthritis and IgA nephropathy. ( 29536978 )
2018
6
Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy. ( 28904360 )
2017
7
Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. ( 28057871 )
2017
8
A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. ( 29279511 )
2017
9
Association of Interleukin-10 Polymorphisms (rs1800872, rs1800871, and rs1800896) with Predisposition to IgA Nephropathy in a Chinese Han Population: A Case-Control Study. ( 28359052 )
2017
10
[Role of IgG antibody to galactose-deficient IgA1 in children with IgA nephropathy]. ( 28881511 )
2017
11
Risk alleles for IgA nephropathy-associated SNPs conferred completely opposite effects to idiopathic membranous nephropathy in Chinese Han. ( 28929317 )
2017
12
ANCA-positive IgA nephropathy without necrotising or crescentic glomerulonephritis: a clinical conundrum. ( 29170179 )
2017
13
MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy. ( 27796698 )
2017
14
Rapidly progressive glomerulonephritis due to anti-glomerular basement membrane disease accompanied by IgA nephropathy: An unusual association. ( 29265054 )
2017
15
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017
16
ANCA and IgA glomerulonephritis all in one: prognosis and complications. ( 29018146 )
2017
17
Plasma Gelsolin Induced Glomerular Fibrosis via the TGF-I^1/Smads Signal Transduction Pathway in IgA Nephropathy. ( 28208683 )
2017
18
The Association of rs1047763 and rs1008898 of C1GALT1 with IgA Nephropathy Risk: A Global Meta-Analysis. ( 28636500 )
2017
19
Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han population. ( 28636766 )
2017
20
Up-regulation of CX3CR1 on tonsillar CD8-positive cells in patients with IgA nephropathy. ( 28196748 )
2017
21
Non-infectious aortitis in an immunosuppressed renal transplant recipient with IgA nephropathy. ( 29054943 )
2017
22
Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: Correlation with clinical features and StreptococcusA pyogenes infection. ( 28260100 )
2017
23
Identification of potential biomarkers and therapeutic targets for human IgA nephropathy and hypertensive nephropathy by bioinformatics analysis. ( 28713898 )
2017
24
Association Between IFN-I^ Gene Polymorphisms and IgA Nephropathy in a Chinese Han Population. ( 28391282 )
2017
25
CCL20 secreted from IgA1-stimulated human mesangial cells recruits inflammatory Th17 cells in IgA nephropathy. ( 28552941 )
2017
26
Association of Megsin Gene Variants With IgA Nephropathy in Northwest Chinese Population: A STROBE-Compliant Observational Study. ( 26871801 )
2016
27
In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. ( 26581012 )
2016
28
Urinary Periostin Excretion Predicts Renal Outcome in IgA Nephropathy. ( 27802442 )
2016
29
Clinical effects of perazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules for treatment of children with IgA nephropathy. ( 27347034 )
2016
30
Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. ( 26986150 )
2016
31
Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy. ( 27900334 )
2016
32
Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. ( 27129712 )
2016
33
Identification of G8969>A in mitochondrial ATP6 gene that severely compromises ATP synthase function in a patient with IgA nephropathy. ( 27812026 )
2016
34
Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity. ( 27127888 )
2016
35
Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy. ( 26825529 )
2016
36
Proteinuria rebound in IgA nephropathy associated with obesity-related glomerulopathy. ( 28508962 )
2016
37
Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases. ( 27624606 )
2016
38
IgA Nephropathy in a Patient Presenting with Pseudotumor Cerebri. ( 26989531 )
2016
39
A case of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome complicated by IgA nephropathy with nephrotic syndrome. ( 28509162 )
2016
40
miR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy. ( 27264483 )
2016
41
The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy. ( 26914454 )
2016
42
Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese. ( 26940089 )
2016
43
Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk. ( 27788494 )
2016
44
Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy. ( 27437939 )
2016
45
Aberrant Blood Vessel Formation Connecting the Glomerular Capillary Tuft and the Interstitium Is a Characteristic Feature of Focal Segmental Glomerulosclerosis-like IgA Nephropathy. ( 27068024 )
2016
46
Low I+-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction. ( 27358498 )
2016
47
MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1I^ in mesangial cells activated by secretory IgA from IgA nephropathy patients. ( 27542871 )
2016
48
Novel therapy for anti-glomerular basement membrane disease with IgA nephropathy: A case report. ( 27168822 )
2016
49
Diffuse alveolar hemorrhage in IgA nephropathy: case series and systematic review of the literature. ( 26845236 )
2016
50
NLRP3 Localizes to the Tubular Epithelium in Human Kidney and Correlates With Outcome in IgA Nephropathy. ( 27093923 )
2016
Sources

Variations for Iga Glomerulonephritis

About this section
Sources

Expression for Iga Glomerulonephritis

About this section
Search GEO for disease gene expression data for Iga Glomerulonephritis.
Sources

Pathways for Iga Glomerulonephritis

About this section

Pathways related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Complement Pathway 64
Show member pathways
 11.66 CFP MASP1 MBL2
2
AGE-RAGE signaling pathway in diabetic complications 37
11.6 AGTR1 CCL2 TGFB1
3
Angiogenesis (CST) 4
11.53 CCL2 REN TGFB1
4
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.41 NPHS1 NPHS2 TGFB1
5
Renin secretion 37
11.31 ACE AGTR1 REN
6
Staphylococcus aureus infection 37
11.18 FCAR MASP1 MBL2
7
Malaria 37
11.02 CCL2 CD40LG TGFB1
8
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 61
Show member pathways
 10.83 ACE AGTR1 REN TGFB1
9
A-beta Pathways: Uptake and Degradation 65
10.64 ACE CCL2 CD40LG
Sources

GO Terms for Iga Glomerulonephritis

About this section

Cellular components related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ACE ALB CCL2 CD40LG CFP FCAR
2 extracellular space GO:0005615 9.36 ACE ALB CCL2 CD40LG CFP MASP1
3 slit diaphragm GO:0036057 9.16 NPHS1 NPHS2

Biological processes related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.65 REN SCGB1A1 TGFB1
2 complement activation GO:0006956 9.58 CFP MASP1 MBL2
3 amyloid-beta metabolic process GO:0050435 9.46 ACE REN
4 regulation of blood vessel diameter GO:0097746 9.43 ACE AGTR1
5 angiotensin maturation GO:0002003 9.37 ACE REN
6 complement activation, lectin pathway GO:0001867 9.32 MASP1 MBL2
7 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.26 ACE AGTR1
8 kidney development GO:0001822 9.26 ACE AGTR1 C1GALT1 REN
9 renin-angiotensin regulation of aldosterone production GO:0002018 9.16 AGTR1 REN
10 mononuclear cell proliferation GO:0032943 8.62 ACE TGFB1

Molecular functions related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1
Sources

Sources for Iga Glomerulonephritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....